Advanced in Myeloproliferative Neoplasms (MPN)

Ofir Wolach

Petah Tiqwa, M, IL 
Advanced in Myeloproliferative Neoplasms (MPN)
Petah Tiqwa, M, IL 
OverviewLocationsClinical Research

Overview

Ofir Wolach practices in Petah Tiqwa, Israel. Mr. Wolach is rated as an Advanced expert by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Agranulocytosis, Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplant.

His clinical research consists of co-authoring 94 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Myeloproliferative Neoplasms (MPN).

Gender
Male

Locations

Petah Tiqwa, M, Israel
Other Locations
Tel Aviv, TA, Israel
Tel Litwinsky, TA, Israel
Ramat Aviv, TA, Israel
Ramat Gan, TA 52621, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2b Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML), Not Eligible for Standard Induction Therapy
A Phase 2b Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML), Not Eligible for Standard Induction Therapy
Enrollment Status: Completed
Publish Date: July 27, 2023
Intervention Type: Drug
Study Drug: Cytarabine
Study Phase: Phase 2
A Phase 2a, Open-Label, Two Stage Study: Stage A: Dose-Range Finder Study to Assess the Safety and Efficacy of Two Doses of Nerofe and Two Doses of Nerofe in Combination With Doxorubicin in Subjects With Acute Myelogenous Leukemia or High Risk Myelodysplastic Syndrome (AML/High Risk MDS). Stage B: Dose Confirmation Study to Assess the Safety and Efficacy of Nerofe or Nerofe in Combination With Doxorubicin in Subjects With AML/ High Risk MDS
A Phase 2a, Open-Label, Two Stage Study: Stage A: Dose-Range Finder Study to Assess the Safety and Efficacy of Two Doses of Nerofe and Two Doses of Nerofe in Combination With Doxorubicin in Subjects With Acute Myelogenous Leukemia or High Risk Myelodysplastic Syndrome (AML/High Risk MDS). Stage B: Dose Confirmation Study to Assess the Safety and Efficacy of Nerofe or Nerofe in Combination With Doxorubicin in Subjects With AML/ High Risk MDS
Enrollment Status: Withdrawn
Publish Date: July 31, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

94 Total Publications

Beating the STATs: targeting the metabolome in acute myeloid leukemia.
Beating the STATs: targeting the metabolome in acute myeloid leukemia.
Journal: Haematologica
Published: August 11, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Wolach's expertise for a condition
ConditionClose
    View All 28 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile